Spots Global Cancer Trial Database for hormone receptor positive (hr+)
Every month we try and update this database with for hormone receptor positive (hr+) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea | NCT05132101 | Metastatic Brea... | Patients who re... | 18 Years - | Pfizer | |
| Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan | NCT05153187 | Breast Cancer | - | Pfizer | ||
| Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. | NCT05155566 | Breast Cancer M... | 18 Years - | Pfizer | ||
| Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan | NCT05153187 | Breast Cancer | - | Pfizer | ||
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | NCT04895358 | Breast Neoplasm... | pembrolizumab paclitaxel nab-paclitaxel liposomal doxor... capecitabine normal saline dextrose | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | NCT04895358 | Breast Neoplasm... | pembrolizumab paclitaxel nab-paclitaxel liposomal doxor... capecitabine normal saline dextrose | 18 Years - | Merck Sharp & Dohme LLC | |
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea | NCT05132101 | Metastatic Brea... | Patients who re... | 18 Years - | Pfizer | |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | NCT06369285 | Hormone Recepto... Metastatic Brea... Recurrent Breas... | Alisertib Endocrine thera... | 18 Years - | Puma Biotechnology, Inc. | |
| Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | NCT02404051 | Metastatic Brea... Breast Cancer Hormone Recepto... Human Epidermal... Locally Advance... | Everolimus Exemestane Fulvestrant | 18 Years - | Consorzio Oncotech | |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy | NCT04030728 | Metastatic Brea... Advanced Breast... | 18 Years - | Onco Medical Consult GmbH | ||
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea | NCT05132101 | Metastatic Brea... | Patients who re... | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
